A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
Recruiting · NCT07231458 · Registry updated 2026-01-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies | Advanced Solid Tumors | Recruiting | Phase 1 | 2026-01-16 | NCT07231458 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Abalos Therapeutics GmbH | 1 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Charite-Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF) | Berlin | Germany | 1 |
| Hospital Universitario Fundacion Jimenez Diaz | Madrid | Spain | 63 |
| The START Center for Cancer Care - CIOCC | Madrid | Spain | 1 |
| Universitaetsklinikum Tuebingen | Tübingen | Germany | 29 |
| Vall d'Hebron Institut d'Oncologia | Barcelona | Spain | 3 |